Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 3
Submit an article Journal homepage
149
Views
16
CrossRef citations to date
0
Altmetric
Theme: Diabetes, Obesity & Metabolic Syndrome - Review

Potential cardiovascular effects of incretin-based therapies

Carolyn F Deacon Department of Biomedical Sciences, Panum Institute, Blegdamsvej 3, DK-2200 Copenhagen, Denmark. [email protected]; Department of Biomedical Sciences, Panum Institute, Blegdamsvej 3, DK-2200 Copenhagen, Denmark. [email protected]
&
Nikolaus Marx Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany; Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany
Pages 337-351 | Published online: 10 Jan 2014

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Carolyn F Deacon & Jens J Holst. (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy 14:15, pages 2047-2058.
Read now

Articles from other publishers (15)

Christian Anholm, Preman Kumarathurai, Lene Rørholm Pedersen, Amirsalar Samkani, Rosemary L. Walzem, Olav Wendelboe Nielsen, Ole Peter Kristiansen, Mogens Fenger, Sten Madsbad, Ahmad Sajadieh & Steen Bendix Haugaard. (2019) Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis 288, pages 60-66.
Crossref
Clifford J. Bailey & Nikolaus Marx. (2019) Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. Diabetes, Obesity and Metabolism 21:1, pages 3-14.
Crossref
C. Santucci, M. Franchi, L. Staszewsky, C. La Vecchia, R. Latini, L. Merlino, G. Corrao & C. Bosetti. (2018) Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. Diabetes Research and Clinical Practice 146, pages 172-179.
Crossref
Carolyn F. Deacon. (2018) A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism 20, pages 34-46.
Crossref
Emilie S. Andersen, Carolyn F. Deacon & Jens J. Holst. (2017) Do we know the true mechanism of action of the DPP ‐4 inhibitors? . Diabetes, Obesity and Metabolism 20:1, pages 34-41.
Crossref
Thorsten Siegmund. (2017) Was passt, was nicht?Combination of oral antidiabetic drugs: What fits together?. MMW - Fortschritte der Medizin 159:13, pages 47-52.
Crossref
Thorsten Siegmund. (2016) Kardiale Effekte aktueller Antidiabetika. CardioVasc 16:3, pages 38-42.
Crossref
Thorsten Siegmund. (2016) Wie hoch ist der Patientennutzen wirklich?Modern antihyperglycaemic agents — what is the patient benefit?. MMW - Fortschritte der Medizin 158:7, pages 46-50.
Crossref
Hala Ahmadieh & Sami T. Azar. (2014) The role of incretin-based therapies in prediabetes: A review. Primary Care Diabetes 8:4, pages 286-294.
Crossref
Borje Darpo, Meijian Zhou, Jessica Matthews, Hui Zhi, Malcolm A. Young, Caroline Perry & Rickey R. Reinhardt. (2014) Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study. Diabetes Therapy 5:1, pages 141-153.
Crossref
Michishige Terasaki, Masaharu Nagashima, Kyoko Nohtomi, Kyoko Kohashi, Masako Tomoyasu, Kyoko Sinmura, Yukinori Nogi, Yuki Katayama, Kengo Sato, Fumiko Itoh, Takuya Watanabe & Tsutomu Hirano. (2013) Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice. PLoS ONE 8:8, pages e70933.
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Gábor Winkler. (2013) Pleiotropic effects of incretins and antidiabetics with incretine mechanism. Orvosi Hetilap 154:7, pages 248-255.
Crossref
Samuel S Engel, Gregory T Golm, Deborah Shapiro, Michael J Davies, Keith D Kaufman & Barry J Goldstein. (2013) Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular Diabetology 12:1, pages 3.
Crossref
J. J. Holst & T. Vilsbøll. (2013) Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism 15:1, pages 3-14.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.